Back

Altesa reports reduced inflammatory biomarkers with vapendavir in COPD study

Verifying
  • Altesa BioSciences presented vapendavir data showing reduced inflammatory biomarkers in rhinovirus-challenged COPD patients.
  • 900 COPD patients are planned for enrollment in the multinational CARDINAL trial across the US and UK.
  • The 2026 findings extend 2025 results on viral load, illness severity, symptoms and quality of life.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.